Previsioni
Il prezzo obiettivo medio degli analisti è 910,05 € (-6,67%). La mediana è 911,35 € (-6,54%).
| Acquista |
Â
25 |
| Mantieni |
Â
6 |
| Vendi |
Â
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Alluvium raises McKesson stake after management reiterates 13–16% long‑term growth target
Alluvium Asset Management said it increased its position in McKesson after the drug distributor reported full‑year results in line with expectations and management reaffirmed 13–16% long‑term earnings growth. The fund’s valuation model rose about 18% versus the share price, leading McKesson to represent 6.8% of the Conventum – Alluvium Global Fund. McKesson closed at $899.56 on September 15, with a 52‑week gain near 30% and recent analyst commentary describing its FY27 outlook as "good enough." » Altro su finance.yahoo.com
McKesson raises full-year outlook after oncology expansion
At the Morgan Stanley Healthcare Conference, McKesson raised its EPS outlook for 2027 to $44.20–45.00 and sees reported growth of 13–15%. Strong results in the Oncology and Multispecialty segment and expansion in oncology and biopharma services—including the planned acquisition of Precision Medicine Group—are driving the improvement. The med-surg business is under pressure, while buybacks, higher dividends and a planned spinoff of Wellverse support capital allocation and shareholder returns. » Altro su de.investing.com
McKesson to buy Precision Medicine Group for $2.25 billion as oncology growth accelerates
McKesson plans to acquire Precision Medicine Group for $2.25 billion to add oncology-focused CRO, clinical-trial and market-access capabilities to its Oncology and Multi-Specialty segment, subject to regulatory approval. The company reported strong first-quarter results, with North American Pharmaceutical Distribution revenue up ~5% and Oncology and Multi-Specialty revenue and profit rising about 33% and 41%, respectively. McKesson expects to return roughly $5 billion to shareholders this year, including $2.5 billion in buybacks and a 15% dividend increase, while continuing investments in automation, AI and other growth initiatives. The firm is also progressing with the separation of its Medical-Surgical business, rebranded as Wellverse, targeted for the back half of next year. » Altro su finance.yahoo.com
McKesson buys Precision Medicine Group for $2.25 billion to boost oncology
McKesson will acquire Precision Medicine Group for about $2.25 billion to expand its Oncology & Multispecialty business with clinical research, lab testing and commercialization services. The deal aligns with McKesson's strategy of exiting non-core assets and investing in higher-growth specialty and oncology areas. Management expects the acquisition to strengthen clinical trial execution and biopharma offerings, but no closing timeline was provided and integration, scalability and near-term earnings impact remain uncertain. » Altro su finance.yahoo.com
McKesson buys Precision Medicine Group for $2.25 billion, strengthens oncology segment
McKesson has signed a definitive agreement to acquire Precision Medicine Group for about $2.25 billion, a move investors view as expanding its oncology and multispecialty strategy. Precision Medicine Group provides clinical research services, biomarker analysis, laboratory services and commercialization support for biotech and pharma companies. The acquisition follows a restructuring that refocused McKesson on higher-margin, faster-growing areas; its oncology and multispecialty business recently grew by 33%. analyst backing and a dividend increase have supported the positive market reaction; the stock rose sharply intraday and is approaching its 52-week high. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheNel 2026, McKesson ha già distribuito 2,97 € di dividendi. L'ultimo pagamento è avvenuto a ottobre.
Dati finanziari
Nell'ultimo trimestre, McKesson ha registrato ricavi pari a 97,96 Mld € e un utile netto di 1,08 Mld €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 97,96Â Mld | 11,45% |
| Utile lordo | 3,49Â Mld | 15,71% |
| Utile netto | 1,08Â Mld | 13,69% |
| EBITDA | 1,65Â Mld | 16,55% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 111,76 Mld € |
Numero di azioni | 115,46Â Mln |
Massimo/minimo a 52 settimane | 1022,08 € - 659,53 € |
Rendimento da dividendo | 0,30% |
Dividendi TTM | 2,96 € |
Beta | 0,28 |
Rapporto P/E | 27,20 |
Rapporto PEG | 1,29 |
Rapporto P/B | -31,24 |
Rapporto P/S | 0,29 |
Profilo aziendale
McKesson Corporation fornisce servizi sanitari negli Stati Uniti e a livello internazionale. Opera attraverso quattro segmenti: U.S. Pharmaceutical, International, Medical-Surgical Solutions e Prescription Technology Solutions (RxTS). Il segmento U.S. Pharmaceutical distribuisce farmaci branded, generici, specialistici, biosimilari e da banco, nonché altri prodotti legati all'assistenza sanitaria. Questo segmento fornisce anche soluzioni di gestione dello studio, tecnologiche, di supporto clinico e di business a studi oncologici di comunità e ad altri studi specialistici; e servizi di consulenza, outsourcing, tecnologici e di altro tipo, oltre a vendere soluzioni finanziarie, operative e cliniche alle farmacie. Il segmento International offre servizi di distribuzione a clienti grossisti, istituzionali e al dettaglio in 13 paesi europei e in Canada. Il segmento Medical-Surgical Solutions fornisce distribuzione di forniture medico-chirurgiche, logistica e altri servizi ai fornitori di assistenza sanitaria. Il segmento RxTS si rivolge a partner e pazienti del settore biofarmaceutico e delle scienze della vita per affrontare le sfide legate ai farmaci lungo il percorso dei pazienti; collega farmacie, fornitori, pagatori e aziende biofarmaceutiche per offrire soluzioni innovative di accesso e aderenza terapeutica; e fornisce servizi di logistica di terze parti e soluzioni di supporto alla distribuzione all'ingrosso. McKesson Corporation è stata fondata nel 1833 ed ha sede a Irving, Texas.
| Nome | McKesson |
| CEO | Brian S. Tyler |
| Sede centrale | Irving,
tx Stati Uniti |
| Sito web | |
| Settore | SanitĂ |
| Industria | Fornitori e servizi sanitari |
| Quotazione in borsa | 10/11/1994 |
| Dipendenti | 42.300 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | MCK |
London Stock Exchange | 0JZU.L |
Frankfurt | MCK.F |
DĂĽsseldorf | MCK.DU |
London | 0JZU.L |
SIX | MCK.SW |
MĂĽnchen | MCK.MU |